Since these nuclear receptors show large interspecies differences, accurate prediction of nuclear receptor mediated CYP3A4 induction in humans requires the use of human systems. As primary cultures of human hepatocytes or enterocytes have major drawbacks like poor availability and poor reproducibility, human cell lines are a good alternative. In this study, the widely used HepG2 cell line was compared the LS180 cell line to serve as a model to study CYP3A4 induction. There was a clear difference between the cell lines with respect to CYP3A enzyme expression and induction. In LS180 CYP3A4 was expressed and was found to be induced by prototypical nuclear receptor agonists, while in HepG2 CYP3A4 was non-responsive to treatment with rifampicin, CITCO or calcitriol. We subsequently evaluated if these host-cell differences also have an effect on CYP3A4 reporter gene activity. We clearly show that there are differences in CYP3A4 reporter activity between the cell lines, and based on these results and those found on mRNA and protein level, we conclude that LS180 is a more suitable cell line to study CYP3A4 induction than the widely used HepG2.
Introduction
The risk of clinically relevant drug-drug interactions that involve the highly inducible cytochrome P450 (CYP) 3A enzyme CYP3A4 is significant, because CYP3A4 has a wide substrate specificity and is involved in the biotransformation of more than 50% of all clinically used drugs (Anzenbacher and Anzenbacherova, 2001 ).
Therefore, several strategies to study CYP3A4 induction have been developed.
Phenotyping studies, such as the erythromycin breath test, can be used directly to measure CYP induction in humans. However, this method has some serious disadvantages like the invasive administration of probe substances to humans, laborintensive protocols, large interindividual differences and difficulties in processing and interpreting the results. Also the use of animals, for both in vivo and in vitro studies, poses problems, because there are large interspecies differences in the CYP3A4 induction capacity of compounds (Lehmann et al., 1998) . Therefore, CYP3A4 induction is mainly studied in vitro in primary cultures of human hepatocytes, which are considered to mostly resemble the in vivo situation. However, the interindividual donor variability, rapid loss of drug metabolizing enzyme expression, poor availability, and the costs are major drawbacks (Brandon et al., 2003) .
The finding that the highly promiscuous pregnane X receptor (PXR; NR1I2) (Moore et al., 2000) is one of the main regulators of CYP3A4 induction has led to the development of CYP3A4 reporter gene assays. These assays are based on the transient transfection of a cell line with a CYP3A4 reporter construct containing the response elements of PXR located in the proximal (-362/+53) and distal (-7836/-7208) promoter regions of the CYP3A4 gene linked to a firefly-luciferase or other reporter genes such as alkalinephosphatase (Goodwin et al., 1999) . In contrast to hepatocytes, many cell lines express lower levels or even no PXR (Thummel et al., 2001; Swales et DMD #17335 6 al., 2003; Phillips et al., 2005) . Therefore cell lines used for the reporter gene assay are often co-transfected with a PXR expression plasmid to increase the levels of this nuclear receptor. Since two other nuclear receptors, the constitutive androstane receptor (CAR; NR1I3) (Kawamoto et al., 1999) and the vitamin D receptor (VDR; NR1I1) (Kolars et al., 1992) , are also known to regulate CYP3A4 induction, cells can also be co-transfected with CAR or VDR instead of PXR. At the moment cell-based reporter gene assays have become suitable alternatives to primary cultures of human hepatocytes to study nuclear receptor mediated CYP3A4 induction. Although nuclear receptor expression levels in these reporter gene assays are raised artificially, a good correlation between PXR-mediated CYP3A4 induction measured in a reporter gene assay, and CYP3A4 mRNA (Roymans et al., 2005) and protein (Luo et al., 2004) expression in primary cultures of human hepatocytes was reported. Furthermore, by comparing CYP3A4 reporter gene assay data and known data on CYP3A4 induction in vivo, Persson et al. (2006) showed that a CYP3A4 reporter gene assay is a reliable screening method for the assessment of drug-induced CYP3A4 expression (Persson et al., 2006) . Currently, the cell line most often used in CYP3A4 reporter gene assays is the human hepatocarcinoma-derived HepG2 cell line (Ogg et al., 1997; Ogg et al., 1999; El-Sankary et al., 2001; Luo et al., 2004; Trubetskoy et al., 2005; Noracharttiyapot et al., 2006; Sinz et al., 2006; Huang et al., 2007) . However, HepG2 mainly expresses the fetal enzyme CYP3A7 instead of CYP3A4 (Schuetz et al., 1993) . In addition, despite the presence of endogenous PXR, CYP3A4 expression is not enhanced by rifampicin treatment in HepG2 cells (Ogino et al., 2002) . Since CYP3A4 is also present in the gastrointestinal tract, and has been shown to contribute significantly to the pre-hepatic metabolism of drugs (Kolars et al., 1992) , other groups use the human DMD #17335 7 colon carcinoma-derived LS180 cell line as a host for their CYP3A4 reporter gene assay (Synold et al., 2001; Zhou et al., 2004) . In contrast to HepG2, rifampicin was shown to increase CYP3A4 expression in LS180 cells (Schuetz et al., 1996) Moreover, in a comparison between three colon carcinoma cell lines (LS180, CaCo-2 and TC-7) only LS180 showed inducible CYP3A4 expression (Pfrunder et al., 2003) .
The aim of this study was to investigate the suitability of LS180 cells as a model to study CYP3A4 induction in comparison with the widely used HepG2 cell line. Therefore, CYP3A mRNA and protein expression levels in both cell lines were determined after treatment with prototypical nuclear receptor agonists (rifampicin (PXR), CITCO (CAR), calcitriol (VDR)) that are known inducers of CYP3A4.
Furthermore, the use of these cell lines as hosts for CYP3A4 reporter gene assays was evaluated.
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Materials and methods
Materials
All cell culture media and supplements were purchased from Invitrogen 
RNA Extraction and RT-PCR
Total RNA was extracted using the GeneElute Mammalian total RNA miniprep kit (SigmaAldrich, Zwijndrecht, The Netherlands). RNA integrity and quantity were determined using a Nanodrop Diode Array Spectrophotometer (Isogen Life Science, IJsselstein, The Netherlands). 1 µ g of total RNA was reverse transcribed according to the manufacturer guidelines concerning the random hexamer primer (RevertAid  First Strand cDNA synthesis kit, Fermentas, St.Leon-Rot, Germany).
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Quantitative RT-PCR
The CYP3A4, CYP3A5, CYP3A7, and 18S mRNA expression levels were analyzed using an ABI Prism 7700 sequence detection system (Applied Biosystems, Foster City, CA, USA). All reactions were singleplexed with 18S. Oligonucleotide primers and a Taqman probe for CYP3A4 were as follows: forward, TCAATAACAGTCTTTCCATTCCTCAT; reverse, CTTCGAGGCGACTTTCTTTCA; and probe, TGTTTCCAAGAGAAGTTACAAA.
The primers and probe used for 18S, CYP3A5 (Hs00241417_m1), and CYP3A7
(Hs00426361_m1) real-time PCR were commercially available Assay on Demand kits (Applied Biosystems, Foster City, CA, USA). According to manufacturer guidelines, data were expressed as threshold cycle value (ct) and used to determine dct values.
Fold changes in expression were calculated according to the transformation: fold increase = 2 -(difference in dct) .
Immunoblot analysis
After 48 
Statistical analysis
Data were analyzed by using one-way ANOVA and the means were compared by applying the Bonferroni post-hoc test and were considered statistically significant when P < 0.05. The correlation between the data obtained from the CYP3A4 reporter gene assays and the protein expression levels were determined using the Pearson correlation coefficient. All statistical determinations were performed with SPSS v14.
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Results
Inducible expression of CYP3A mRNA in LS180 and HepG2
First we considered which CYP3A enzymes are induced following treatment with rifampicin, CITCO and calcitriol in LS180 and HepG2. As shown in figure 1, in LS180 a significant increase of CYP3A4 mRNA expression was observed after exposure to rifampicin and calcitriol, while a less marked induction of CYP3A5 mRNA expression was observed following treatment with these compounds. CITCO however did not affect CYP3A4, CYP3A5 or CYP3A7 mRNA expression in LS180.
In HepG2 no significant increase in CYP3A mRNA expression was detected after exposure to rifampicin, CITCO or calcitriol.
Inducible expression of CYP3A protein in LS180 and HepG2
The CYP3A protein response profile after exposure to rifampicin, CITCO or calcitriol was examined in LS180 and HepG2 using Western immunoblotting. As shown in figure 2, inducible expression of CYP3A protein was detected after exposure to rifampicin and calcitriol in LS180. CITCO did not increase CYP3A protein expression in LS180 cells. In HepG2 the protein expression of CYP3A was very low and was not induced after treatment with the prototypical nuclear receptor agonists rifampicin, CITCO and calcitriol (data not shown).
Effect of endogenously expressed nuclear receptors on CYP3A4 reporter activity
To evaluate the effect of endogenously expressed nuclear receptors on the CYP3A4 reporter gene activity, LS180 and HepG2 cells were transiently transfected with the CYP3A4 reporter construct and an "empty" nuclear receptor expression plasmid. The transfected cells were treated with the corresponding nuclear receptor DMD #17335 14 agonists. Treatment of LS180 with 100 nM calcitriol for 48 hours resulted in a major increase in CYP3A4 reporter activity (figure 3). In HepG2 also an increase in CYP3A4 reporter gene activity was observed after treatment with calcitriol, but it was much lower compared to the CYP3A4 reporter activity in LS180. This indicates that both cell lines express functional endogenous VDR. Exposure to rifampicin led to a small, but significant (P<0.05) increase in CYP3A4 reporter gene activity in LS180, but not in HepG2, indicating the presence of functional endogenous PXR in LS180.
CITCO did not significantly increase CYP3A4 reporter activity in both LS180 and HepG2 compared to the vehicle 0.1% DMSO, which indicates that both cell lines do not express high levels of functional CAR.
CYP3A4 reporter gene activity in LS180 and HepG2
To examine the influence of the host cell line on the activity of the CYP3A4 reporter gene assay in the presence of exogenous PXR, CAR or VDR, LS180 and HepG2 were transiently transfected with the CYP3A4 reporter construct combined with PXR-, CAR-or VDR-expression plasmids, followed by exposure to different concentrations of the corresponding agonists. The CYP3A4 reporter activities in both LS180 and HepG2 as a result of nuclear receptor activation are shown in figure 4.
In LS180 rifampicin, CITCO and calcitriol were able to significantly increase CYP3A4 reporter gene activity compared to the control, while in HepG2 only rifampicin and calcitriol gave a significant increase in CYP3A4 reporter gene activity compared to the control. Moreover, the increase of PXR-and VDR-mediated CYP3A4 reporter activity following treatment with respectively rifampicin and calcitriol in HepG2 was significantly lower (~2 fold) compared to the increase of CYP3A4 reporter gene activity in LS180 after treatment with the same nuclear 
Discussion
In the present study, we explored the suitability of the colon carcinomaderived LS180 cell line for its use in CYP3A4 induction studies compared to the hepatoma-derived HepG2 cell line. HepG2 is still the most widely used cell line in CYP3A regulation and induction studies. Although several groups have already
shown that the HepG2 cell line expresses high levels of the fetal CYP3A enzyme CYP3A7 (Schuetz et al., 1993; Wilkening et al., 2003) . In contrast, LS180 has been shown to express CYP3A4 (Kolars et al., 1992; Schuetz et al., 1996) .
To evaluate the difference in CYP3A enzyme inducibility between HepG2 and LS180, both cells were challenged with the prototypical nuclear receptor agonists rifampicin, CITCO or calcitriol, and mRNA and protein expression were determined.
mRNA analysis of the different CYP3A enzyme expression levels in both cell lines revealed that CYP3A4 and CYP3A5 were induced after treatment with rifampicin or calcitriol in LS180, while none of the CYP3A mRNA enzyme levels in HepG2 were induced after treatment with these agents. Protein expression analysis showed that the expression of CYP3A protein was inducible in LS180 only. The protein levels increased after treatment with the prototypical CYP3A4 inducers rifampicin and calcitriol. Although the antibody used could not discriminate between the CYP3A4 and CYP3A7 enzymes, it can be assumed that CYP3A4 protein expression levels in this cell line were induced based on the results of the mRNA analysis, which clearly show that only CYP3A4 mRNA expression levels are inducible following treatment with these compounds.
In HepG2, CYP3A protein was hardly detectable even after treatment with rifampicin, CITCO or calcitriol. This is consistent with the mRNA analysis data, which also show no CYP3A induction after treatment with the same compounds.
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Furthermore, as mentioned before HepG2 expresses CYP3A7, which is not induced by rifampicin (Krusekopf et al., 2003; Usui et al., 2003) . Krusekopf only observed pronounced CYP3A7 induction in HepG2 after treatment with typical human glucocorticoid receptor (hGR) agonists indicating an important role for the hGR in CYP3A7 regulation. Furthermore, the promoter sequence of the CYP3A7 gene has two mutations in the proximal ER6 repeat, which has implications for binding of nuclear receptors of the NR1I family (e.g. PXR, CAR, VDR). These mutations lead to less pronounced binding of liganded VDR to the CYP3A7 promoter resulting in a loss of gene activation after calcitriol treatment (Hara et al., 2004) . Since PXR also recognizes and binds to ER6 repeats, the mutations may affect the binding of PXR to the CYP3A7 promoter as well, which could explain the lack of response to rifampicin treatment of HepG2 cells with respect to CYP3A7 induction.
The results discussed above clearly show that HepG2 and LS180 have distinct CYP3A induction profiles. We therefore evaluated if this alternate expression pattern also affects CYP3A4 reporter activity. Indeed, in the CYP3A4 reporter gene assay, both cell lines clearly showed distinct responses after treatment with the prototypical nuclear receptor agonists. Treatment of LS180 and HepG2 that were transfected with CYP3A4 reporter constructs without contransfection of nuclear receptor expression plasmids, resulted in a significant (p<0.05) increase of reporter activity after treatment with rifampicin and calcitriol in the LS180 cell line. These results indicate that functional PXR and VDR are endogenously expressed in this cell line.
The most pronounced effect on CYP3A4 reporter activity was found when both cell lines were co-transfected with the nuclear receptor expression plasmids of PXR or VDR and subsequently treated with the corresponding agonists. Comparison of the CYP3A4 reporter activities in LS180 and HepG2 cells after PXR or VDR activation DMD #17335 18 revealed that there was a significant difference in the increase of CYP3A4 reporter activity between the cell lines. The fold induction of CYP3A4 reporter activity in LS180 cells was about 2 fold higher for both nuclear receptors than the fold induction in HepG2.
The CYP3A4 reporter activities in the presence of PXR expression plasmid in LS180 showed a good correlation with CYP3A4 protein expression levels, which in turn were in concordance with CYP3A4 protein expression levels found in primary cultures of human hepatocytes that were treated with rifampicin (Hariparsad et al., 2004) . In the case of calcitriol, however, the CYP3A4 protein levels were twice as high in LS180 as in human hepatocytes (Kolars et al., 1992) . This difference is probably a result of the high endogenous expression of VDR in LS180. The high endogenous VDR expression may cause problems with respect to CYP3A4 reporter gene assays that are co-transfected with other nuclear receptors such as PXR, because PXR and VDR bind to the same response elements within the promoter region of the CYP3A4-luciferase construct. However, in contrast to the highly promiscuous PXR, VDR has a very narrow ligand specificity and only bile acids and vitamin D derivatives are known to activate this receptor (Makishima et al., 2002; Hara et al., 2004) . Therefore, although endogenous VDR expression is high in LS180 cells, it still is a suitable cell line to study the effect of xenobiotics on CYP3A4 induction, as most compounds exert their effect on CYP3A4 expression through the more promiscuous PXR (Lehmann et al., 1998; Goodwin et al., 1999; El-Sankary et al., 2001 ).
In addition to PXR and VDR, CAR is also able to cross regulate CYP3A4 (Qatanani and Moore, 2005) . Therefore the role of CAR activation on the induction of CYP3A4 was investigated. CAR is, just like PXR (Squires et al., 2004) and VDR (Racz and Barsony, 1999) , located in the cytoplasm in vivo. In contrast to PXR and DMD #17335
19 VDR, CAR translocation is stimulated in a ligand-independent manner.
Phenobarbital, phenytoin and bilirubin have been shown to trigger CAR nuclear translocation without binding to the LBD of CAR. Due to the constitutive activity of CAR, translocation results in transcriptionally activation of its target genes. In HepG2 cells it has been reported that CAR spontaneously translocates to the nucleus due to a lack of cytoplasmic CAR retention protein (CCRP) (Kobayashi et al., 2003) . These results are derived from a representative experiment and data are the means ± SD from three separate determinations and is expressed as absolute reporter activity (significance (* p<0.05)).
